CAR-T is a form of immunotherapy currently approved and under investigation for the treatment of myeloma. Immunotherapy drugs use the body’s immune cells to fight cancer. Here you will find a summary of MPE’s resources on CAR -T therapy:
CAR T-cell therapy side effects (March 2023)
Find the answers to the most frequently asked questions about the side effects associated with CAR-T.
Chimeric Antigen Receptor T-cell (CAR-T) therapy (June 2022)
Find the answers to the most frequently asked questions by patients about CAR-T.
The reality of CAR-T therapy: Am I eligible? (March 2021)
Find out about inclusion and exclusion criteria in CAR T-cell clinical trials.
Conference report: European Hematology Association (EHA) (July 2022)
The European Hematology Association (EHA) annual meeting is the most important haematology scientific congress in Europe. This report summarises the most important updates presented in this congress around myeloma, AL amyloidosis and patient advocacy.
Conference report: 4th European CAR T-cell meeting (March 2022)
This report summarises the most important highlights presented in the 4th edition of the European CAR T-cell Meeting jointly organised by the European Hematology Association (EHA) and the European Group for Blood and Marrow Transplantation. (EBMT)
Conference report: The American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Annual Congresses (October 2021)
The ASCO Annual Meeting and The EHA annual meeting are the most important haematology scientific congresses worldwide. This report summarises the most important updates presented in both congresses around myeloma, AL amyloidosis and patient advocacy.
Watch This video interview of Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, talking about CAR T- cell therapy updates from EHA 2022.
Highlights in Myeloma: American Society of Hematology (ASH) (January 2022)
Watch this video interview of Dr Maria-Victoria Mateos, MD, PhD, Director of the Myeloma Unit at the University Hospital of Salamanca-IBSAL, Spain, talking about ASH 2021 highlights.
The highlights are available in the following languages:
Idecabtagene Vicleucel (April 2022)
Idecabtagene vicleucel is a type of CAR-T therapy. The factsheet covers important issues around the treatment so that patients can feel safe and informed when asking their doctor specific questions.
Ciltacabtagene autoleucel (March 2023)
Ciltacabtagene autoleucel (also known as cilta-cel or Carvykti®) is a chimeric antigen receptor T-cell therapy (CAR T-cell therapy).
Doctor and patients’ perspective on myeloma CAR-T (February 2023)
Recording of the webinar that includes the participation of Prof. Dr. Michel Delforge, Professor of Medicine and Clinical Head of Haematology at the University Hospital Leuven, Belgium, and two myeloma patients who have received CAR-T treatment: Tamra Fine, from the Netherlands, and William Kenneth Casler, from France.
Watch the recording of the session “Immunotherapy in the treatment of myeloma and AL amyloidosis”, held at the Myeloma Patients Europe Masterclass 2021. The talk was given by Dr Maria-Victoria Mateos, MD, PhD, Director of the Myeloma Unit at the University Hospital of Salamanca-IBSAL, Spain.
From T-cell collection to CAR T-cell infusion (June 2023)
MPE conducted four written interviews on CAR-T manufacturing to better understand various myeloma CAR-T therapies’ manufacturing processes and challenges.
watch this video recording of Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explaining the advice he would give to myeloma patients who are about to start a CAR-T clinical trial during the COVID-19 pandemic
Watch this video recording of Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explaining if it is safe to participate in a CAR-T trial in myeloma during the COVID-19 outbreak.
The myeloma patient perspective on the use of Patient-Reported Outcomes (PROs) in CAR-T clinical trials
Exploring the patient perspective is vital in shaping the landscape of clinical trials, especially in fields like myeloma where novel treatments, such as CAR-T therapy, present promising yet complex challenges. In this MPE report, ´The Myeloma Patient Perspective on PROs in CAR-T Clinical Trials,´ you can find the research gathered from myeloma patients who have experienced CAR-T therapy. Through a qualitative analysis, we aim to shed light on the utilisation and effectiveness of Patient-Reported Outcome (PROs) measures in myeloma CAR-T clinical trials.
- You can read more about our findings and recommendations in the full report here.
MPE is a stakeholder of this project consortium investigating an autologous CAR T-cell therapy targeting SLAM7. The project aims to bring CAR-T from the laboratory to patients.
Read more about the CARAMBA project in the Myeloma Pipeline information sheet available in the following languages: